We describe specific EMIT#{174} homogeneousenzyme immunoassays for amitnptyline, nortrlptyllne, imipramine, and desipramine in patients' serum samples. Beforeanalysis, aneasily performed extraction step involving the use of 500 4. of sampleand a 1-mL disposable column eliminates crossreactingpolar metabolites.The range of the standardcurve forthe firstthree drugsis 25 to 250g/L, andfordesipramine is50 to 500 
liquid chromatography (HPLC) and gas-liquid chromatography (3, 7, 8). Both methods require skillful technique during sampleextraction and concentration steps (9), highly specialized equipment and methodology (10), and lengthy analysis time. Proficiency testing surveys illustrate the direct effects of the complexities and variations of these chromatographic techniques (11, 12), frequently showing high coefficients of variation (CVs), 20% to 50%, for interlaboratory comparisons of antidepressant assay results.
The EMIT#{174} assays described here are the first quantitative nonisotopic immunoassays for tricyclic antidepressant drugs. A specific EMIT enzyme immunoassay follows a simple solid-phase extraction to remove cross-reacting polar metabolites.
The procedure is less labor-intensive than other methodologies, requires uncomplicated laboratory equipment, and provides a sample throughput of up to 40 samples per hour.
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1Nonstandard abbreviations: AM!, amitriptyline; NORT, nortriptyline; IMI, imiprainine; DESI, desipramine; and HPLC, "highperformance" liquid chromatography.
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Principle
The EMIT assays for tricydic antidepressants are based on the same principle as other standard EMIT assays (13). The drug in the sample eluate competes with the drug-labeled enzyme (glucose-6-phosphate dehydrogenase, EC 1.1.1.43) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts NAD to NADH, resulting in an abeorbance change measured at 340 nm.
In addition to the EMIT technology, the tricycic assays include a sample pretreatment involving extraction columns. Currently, solid-phase columns labeled with various functional groups are used routinely in some chromatographic assays (14-19). Column extraction, an alternative to liquid/liquid extraction, prepares samples for chromatographic analysis by removing endogenous macromolecules and concentrating the analyte(s). We have taken a new approach to sample pretreatment by use of columns. In this procedure, we use the columns primarily as a chromatographic tool to remove cross-reacting metabolites.
All forms of the tricycic antidepressant drugs in the patients' samples are adsorbed onto the column material. The unwanted metabolites are then removed by elution with an acidic buffer/solvent wash solution. This solution is optimized for both pH and dispensed volume to minimize the loss of parent drug. AM!, NORT, IMI, and DESI are subsequently eluted from the column with a mixed-solvent mobile-phase followed by an acidic buffered diluent. The diluent helps minimize evaporation by decreasing the proportion of solvent in the eluate and enhances sample stability by decreasing the pH. Extracts of samples from patients administered amitriptyline will contain both aniitriptyline and nortriptyline, and extracts of samples from patients administered imipramine will contain both imipramine and desipramine. Secificity between the parent drugs and their demethylated metabolites is provided by the antibody used in each EMIT assay.
Internal standards, frequently used in chromatographic assays to monitor and minimize sample-to-sample variations introduced in the extraction and chromatography steps, are not required in the EMIT procedure.
Materials and Methods

Reagents
All of these reagents for performing the extraction step and the enzyme immunoassay are supplied separately by Syva Co. The description of some essential components is proprietary information.
Solid-phase columns. Disposable 1-mL columns packed with covalently labeled silica gel specially prepared and evaluated for use in these assays.
Ancillary reagents. Each set contains one lowconcentration and one high-concentration control (Controls I and LU; these are used together to monitor the slope of the standard curve. The mean assay value for these controls is within 10% of the nominal concentration.
Note that controls ifi, N, and V mentioned in this text were prepared only for in-house method evaluation.
Apparatus
We used the VacEluttM vacuum manifold (Analytichem International, Harbor City, CA 90710) to accommodate the 1-mL disposable columns in the extraction procedure, then assayed the tricyclic drugs with a Syva AutoLab system, which includes the Syva AutoCarousaltm equipped with a Gilford#{174} Stasar ifi spectrophotometer and Syva LP-6500 data processor. All equipment, including the VacElut manifold, is available from Syva Co., Palo Alto, CA 94304.
Goilection and Handlingof Specimens
We recommend using fresh serum or plasma samples. Serum is preferred because fibrin strands, which hinder column flow, may form in some plasma samples during storage (refrigerated or frozen). Serum and plasma separation devices such as gels and ifiters must not be used, because the ifitering material may adsorb tricycic antidepressants.
Blood should not be collected in tubes with stoppers containing the plasticizer tris(2-butoxyethyl) phosphate, because it inhibits the protein-binding of these drugs. An increased concentration of free drug could then migrate into the erythrocytes, decreasing the concentration of the drug measured in serum (2, 20) .
Procedure
Apply the serum samples onto the extraction columns, using a calibrated hand-held pipetter with disposable tips. Pipet the extraction solutions by using accurate and precise repeating dispensers. To ensure column-to-column consistency, perform each pipetting step with the vacuum released.
Just before use, clean and activate each column by washing qualitatively with HPLC-grade methanol (-1 mL) followed by de-ionized or distilled water (-1 mL); discard the eluates. Apply 500 pL of serum (calibrator, control, or patient's sample) onto the column and elute to waste; then add 900 1iL of "wash solution," elute, and discard. Finally, add 500 L of "mobile-phase solution," followed by 1 mL of "extraction diluent" to elute the metabolite-free drug into a test tube. Cap the test tube and thoroughly vortex-mix. The sample extract is now ready for EMIT assay.
Analysis of the extracts is similar to the assay protocol of other EMIT therapeutic drug monitoring assays with the AutoLab system. Fill sample cups with approximately 200 pL of the extract and overlay with "sample seal" to prevent solvent evaporation and sample contamination. Deliver 50 p.L of extract and 250 pL of assay buffer into a reaction cup, follow with 50 L of Reagent A (antibody and substrate) plus another 250 zL of assay buffer. After a 50-s incubation, add 50 pL of Reagent B (drug-labeled enzyme) plus 250 zL of assay buffer. Aspirate this final mixture without delay into the spectrophotometer, which automatically activates the data processor to time and record the change in absorbance. After a 10-s delay, determine the change in absorbance during 50 s. Controls and patients' samples are automatically quantified by comparison with the standard curve. Re-run all AM! and IMI patients' sample and control cups for NORT and DESI, respectively, using the appropriate reagents and calibrators. Up to 40 samples can be evaluated, from extraction to results, within 1 h.
Assay EvaluationStudies
Extract stability. Extracts were evaluated for stability in the test tube and in the AutoLab sample cup overlayed with "sample seal." Extracts stored in the original test tube are stable at 2-8 #{176}C for at least two weeks, and remain quantitatively related to the drug content of the original sample as long as evaporation is prevented. We recommend storage at 2-8 #{176}C, with the test-tube stoppers secured with Paraflim. Extracts placed in sample cups for use in the AutoLab system and completely overlain with "sample seal" are stable for at least 15 h at room temperatures (18-30 #{176}C). Stability in this configuration is convenient when resampling from the same cup is necessary-for instance, when one is measuring NORT or DES! in AM! or IMI samples, respectively.
Dynamic range. These assays were designed to accurately quantify concentrations encompassing the therapeutic ranges of these drugs. Patients' samples with antidepressant content greater than that of the highest concentration calibrator can still be quantified with fair accuracy by diluting the extracted sample with either the eluate from the zero calibrator or a mixture of one volume of "mobilephase solution" with two volumes of "extraction diluent." After diluting the sample, vortex-mix thoroughly and reassay; multiply the result by the dilution factor.
Results and Discussion
Effect of Column Extraction
As Table 1 shows, the extraction step removes many cross-reacting compounds that interfere in the EMIT tricyclic antidepressants assays. The amount of interference observed before extraction cannot be completely explained by the amount of the hydroxy metabolites in the samples, because their typical concentrations in serum (21) (22) (23) (24) (25) would contribute only a small portion to the observed bias. The identification of other interfering metabolites, such as glucuronide conjugates, is difficult owing to the unavailability of standards. Ext.
Un.xt.
Ext. n = 10 each. 
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While developing this protocol, we used the removal of the hydroxy metabolites as an index to extraction efficiency. These metabolites are included in our Control 111(see Table  3 below). As we expected, the other, more hydrophilic metabolites were also eliminated during the extraction because of their greater affinity for the polar "wash solution" than for the hydrophobic column matrix. This accounts for the excellent correlation between the EMiT results for extracted patients' samples and the HPLC results ( Table 1) .
The "wash solution," optimized to remove the maximum amount of metabolite during extraction, also removes some of the parent drug. This results in an absolute recovery of approximately 80%. The percentage varies slightly from analyte to analyte and is influenced by such laboratory variables as pipetting accuracy and temperature.
For example, investigating the effect of extraction temperature on absolute drug recovery, we found that higher temperatures increased the effectiveness of the "wash solution." Therefore, more drug was lost in the wash step. This effect was most dramatic with the least-hydrophobic drug, DES!. Absolute recovery for DES! samples extracted at 18 or 30#{176}C and assayed with calibrators extracted at the same respective temperature averaged 15% less at 30 #{176}C than at 18#{176}C; recovery of AM!, NORT, and TM! changed by <10% (data not shown). On the other hand, analytical recovery of all four drugs quantified with use of calibrators extracted at the same temperature is reflected in the data presented in Table 2 . Evidently, calibrators, controls, and samples should all be extracted during the same period of time-or at least at similar temperatures-to assure consistent and accurate quantification.
Analytical Recovery and Precision
Analytical recovery was determined by use of extracts of drug-supplemented untreated human serum. Aliquots of 10 different serum samples from apparently healthy donors that were negative by EMiT analysis for tricyclic antidepressants were supplemented with each drug alone. Concentrations between those of the first and second calibrators and between those of the fourth and fifth calibrators were between the fourth and fifth calibrators. We evaluated between-run precision by performing daily assays with freshly extracted serum controls over a period of several weeks. We analyzed five controls (I-V) for each assay. Controls ifi, IV, and V are in-house configurations only. Control ifi contains, in addition to the parent drugs, 100 pg of the respective hydroxylated metabolites of both AM! and NORT or IMI and DES! per liter. Because all the controls contained either AM! and NORT or TM! and DES!, we evaluated each control extract twice, once for the tertiary amine drug and again for the respective secondary amine drug. As Table 3 shows, the between-run CVs were <10% throughout the range of the standard curve for each assay.
Cross Reactivity and Specificity
We tested related drugs and drugs occasionally co-administered or abused for cross reactivity in each assay, adding increments of the compound being tested to a sample containing 100 pg each of AMI and NORT per liter and to a 
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sample containing 100 pg of TM! and 200 pg of DES! per liter. We then extracted and quantified the samples. Table 4 lists concentrations of compounds that cause a 30% error in quantification (considered to be both analytically and clinically significant). In most cases, the concentration necessary for such error to occur exceeds that listed. Compounds and their met.abolites that cross react within their respective therapeutic or expected range (21) (22) (23) (24) (25) are indicated in Table  4 by asterisks.
!t is important to note which compounds will interfere with these assays. Results for patients' samples containing more than one tertiary amine drug (AMl, TM!, doxepin, chlorpromazine, or trimipramine) because of recent therapy revision will give too-high results for either AM! or IMI. If more than one secondary amine drug (NORT; DES!; desmethyltrimipramine, the metabolite of trimipramine; nordoxepin, the metabolite of doxepin; and protriptyline) is present, the NORT or DES! measurement will also be erroneously high. Such situations are extremely uncommon. Knowledge of the recent history of a patient's drug therapy is an important safeguard to assure accurate results.
Perphenazine, a phenothiazine coadministered in the amitriptyline preparations Etrafon (Schering) and Triavil#{174} (Merck Sharp and Dohme), does not interfere with the AM! or NORT assay.
Another AM! preparation, Limbitrol#{174} (Roche), contains the benzodiazepine, chiordiazepoxide.
Benzodiazepines, tested here as diazepam, are structurally dissimilar to the tricyclic antidepressants and do not interfere in these assays.
PotentialInterferencefrom EndogenousCompounds
Analytical recovery and precision were evaluated for each drug in samples containing either 0.3 g of total bilirubin (grossly icteric), 4 g of hemoglobin (grossly hemolyzed), or 10 g of triglycerides (grossly lipeniic) per liter. A pooled specimen of serum that was negative for tricycics by EMIT analysis was prepared for each assay. Each such pool was supplemented with one mid-range concentration of drug and then divided into four aliquots: three aliquot.s were further supplemented with either bilirubin, hemoglobin, or triglyceride (test solutions); the fourth served as the experimental control. Each test solution was extracted 10 times and the control pool was extracted 20 times. All extracts for one assay were quantified from the same specific calibration curve. The addition of large volumes of endogenous compounds into each drug-supplemented pool introduced a dilution error of their original drug concentration.
Therefore, the mean assayed concentration of each test solution 1000 50000 30* 50* 1000 1000 was mathematically adjusted upward by the percent dilution error introduced by the endogenous compound. We then compared these "adjusted mean" concentrations with the control value, to determine the percent recovery of tricycic drug.
As Table 5 shows, very high concentrations of bilirubin, hemoglobin, or triglycerides do not adversely affect precision (CVs <10%) or recovery (89-109%) in these EMIT tricyclicantidepressant assays.
Comparative Analysis
Patients' samples previously analyzed by a reference laboratory by HPLC were analyzed in-house by the appropriate EMIT tricycic antidepressant assay. NORT-containing samples were from patients being treated with either AM! or NORT; DES! samples were from patients being treated with either IMI or DES!. Linear regression analysis showed a good correlation between the EMIT assay results and the reference method. Correlation results are suminarized in Table 6 .
During our patient-sample analyses, we found occasional HPLC sample results that did not correlate well with the respective EMiT result. Owing to insufficient sample volume, not all of these samples could be thoroughly re-evaluated, but, for those samples with sufficient volume, results of a repeat HPLC analysis correlated very well with the original EMIT result. We suspect inappropriate sample storage conditions as the primary cause of these discrepancies.
Jn summary: this is a rapid, reliable method for measurement of the tricycic antidepressants AM!, NORT, IMI, and DESI. The convenient protocol allows any laboratory to analyze these drugs accurately in a standard spectrophotometer.
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